Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.

Universitaire Ziekenhuizen KU Leuven29 enrolled

Overview

Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted. In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Heart Failure

Interventions

heart-failure related pharmaceutical interventionOTHER

Eligibility

Sex: ALLMin age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 75 years or older * diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure' * diagnosis had to be confirmed by a recent echocardiogram Exclusion Criteria: * not Dutch speaking * treatment restrictions had been applied on admission

Locations (1)

University Hospitals Leuven

Leuven, Flemish Brabant, Belgium

Outcomes

Primary Outcomes

the number of heart-failure related pharmaceutical interventions

Time frame: during hospital stay (average of 14 days)

Secondary Outcomes

acceptance rate of the pharmaceutical interventions

Time frame: during hospital stay (average of 14 days)

clinical feasibility of the accepted interventions

Time frame: during hospital stay (average of 14 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.